3,4-二氢-1H-喹噁啉-2-酮 | 59564-59-9

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 3,4-二氢-1H-喹噁啉-2-酮
• 中文别名: 3,4-二氢-1H-2-喹喔啉酮
• 英文名称: 1,2,3,4-tetrahydroquinoxalin-2-one
• 英文别名: 3,4-dihydroquinoxalin-2(1H)-one；3,4-dihydro-(1H)-2-quinoxalinone；3,4-dihydro-1H-quinoxalin-2-one
• CAS: 59564-59-9
• 化学式: C₈H₈N₂O
• mdl: MFCD00204133
• 分子量: 148.164
• InChiKey: HYTIPJFUWHYQON-UHFFFAOYSA-N

物化性质

• 熔点：
  140-143℃
• 沸点：
  370.5±31.0 °C(Predicted)
• 密度：
  1.186±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  存储条件：2-8°C，避光，惰性气体保护。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3,4-Dihydro-1h-quinoxalin-2-one
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3,4-Dihydro-1h-quinoxalin-2-one
CAS number: 59564-59-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H8N2O
Molecular weight: 148.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3,4-二氢-1H-喹噁啉-2-酮 在 盐酸 、 硼烷四氢呋喃络合物 、 sodium hydride 、 sodium cyanoborohydride 、 溶剂黄146 、 三乙胺 、 三氟乙酸 、 potassium iodide 、 potassium hydroxide 、 锌 、 sodium nitrite 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醚 、 乙醇 、 水 、 N,N-二甲基甲酰胺 、 异丙醇 、 甲苯 、 mineral oil 、 正丁醇 为溶剂， 反应 17.0h， 生成 1-(4-氟苯基)-4-[(6BR,10AS)-2,3,6B,9,10,10A-六氢-3-甲基-1H-吡啶并[3',4':4,5]吡咯并[1,2,3-DE]喹喔啉-8(7H)-基]-1-丁酮对甲苯磺酸盐
  参考文献：
  名称：

  四环喹喔啉衍生物作为治疗神经精神病和神经疾病的有效和口服活性多功能药物候选物的发现

  摘要：

  我们报告了一类四环丁苯酮的合成与结构-活性关系，这些四环丁酮显示了对5-羟色胺5-HT 2A和多巴胺D 2受体的强结合亲和力。这项工作导致了4-（（6b R，10a S）-3-methyl-2,3,6b，9,10,10 a -hexahydro -1 H，7 H -pyrido [3'，4 ′：4,5]吡咯并[1,2,3- de ]喹喔啉-8-基）-1-（4-氟苯基）-丁-1-酮4-甲基苯磺酸盐（ITI-007），其有效值为5 -HT 2A拮抗剂，突触后D 2素和5-羟色胺转运蛋白的抑制剂。该多功能候选药物具有口服生物利用度，并且在体内表现出良好的抗精神病功效。目前，这种正在研究中的新药正在临床开发中，用于治疗神经精神疾病和神经疾病。

  DOI：

  10.1021/jm401958n
• 作为产物：
  描述：

  N-(2-硝基苯基)甘氨酸甲酯 在 palladium 10% on activated carbon 、 氢气 作用下， 以 乙醇 为溶剂， 生成 3,4-二氢-1H-喹噁啉-2-酮
  参考文献：
  名称：

  1,4-二氢喹喔啉-2-酮在可见光下对电子贫烯烃的光催化吉斯加成反应

  摘要：

  使用Ru（bpy）3 Cl 2作为光催化剂和（PhO）2 PO 2 H作为添加剂，实现了1,4-二氢喹喔啉-2-酮与Michael受体的可见光光氧化还原催化偶联。优化的反应条件为具有广泛结构上不同的迈克尔受体的自由基共轭加成产物（44个实例）提供了良好的收率。还描述了使用阳光照射的克级反应。此外，使用Giese添加产品进行了几次转化。

  DOI：

  10.1021/acs.orglett.0c02953

文献信息

• Substituted pyrroloquinoxalinones and diones
  申请人：Eli Lilly and Company

  公开号：US04075206A1

  公开（公告）日：1978-02-21

  Substituted pyrroloquinoxalinones and diones, useful as anti-inflammatory and anti-thrombotic agents.

  取代吡咯喹喔喹啉酮和二酮，可用作抗炎和抗血栓药物。
• Substituted heterocycle fused gamma-carbolines
  申请人：——

  公开号：US20040220178A1

  公开（公告）日：2004-11-04

  The present invention is directed to methods of treating addictive behavior and sleep disorders by administering compounds represented by structural Formula (I) 1 or pharmaceutically acceptable salt forms thereof, wherein R 1 , R 5 , R 6a , R 6b , R 7 , R 8 , R 9 , X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.

  本发明涉及通过给予由结构式（I）表示的化合物或其药学上可接受的盐形式来治疗成瘾行为和睡眠障碍的方法，其中R1、R5、R6a、R6b、R7、R8、R9、X、b、k、m和n以及虚线如本文所述。本发明治疗方法中使用的化合物是5-羟色胺激动剂和拮抗剂，对于控制或预防包括成瘾行为和睡眠障碍在内的中枢神经系统疾病是有用的。
• Formal Deoxygenative Hydrogenation of Lactams Using PN^HP-Pincer Ruthenium Complexes under Nonacidic Conditions
  作者：Osamu Ogata、Hideki Nara、Kazuhiko Matsumura、Yoshihito Kayaki

  DOI：10.1021/acs.orglett.9b03878

  日期：2019.12.20

  amides to amines with RuCl2(NHC)(PNHP) (NHC = 1,3-dimethylimizadol-2-ylidene, PNHP = bis(2-diphenylphosphinoethyl)amine) is described. Various secondary amides, especially NH-lactams, are reduced with H2 (3.0-5.0 MPa) to amines at a temperature range of 120-150 °C with 1.0-2.0 mol % of PNHP-Ru catalysts in the presence of Cs2CO3. This process consists of (1) deaminative hydrogenation of secondary amides

  描述了用RuCl2（NHC）（PNHP）（NHC = 1,3-二甲基亚甲基吲哚-2-亚基，PNHP =双（2-二苯基膦基乙基）胺）将酰胺进行正式的脱氧加氢成胺。在Cs2CO3存在下，在1.0-2.0 mol％的PNHP-Ru催化剂下，在120-150°C的温度范围内，用H2（3.0-5.0 MPa）将各种仲酰胺（尤其是NH-内酰胺）还原为胺。该方法包括（1）仲酰胺的脱氨基加氢生成伯胺和醇，（2）瞬态胺与醇的脱氢偶联生成亚胺，（3）亚胺的加氢生成形式上脱氧的仲胺产物。
• [EN] BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS DE BIARYLE ACÉTAMIDE ET PROCÉDÉS D'UTILISATION DE CEUX-CI
  申请人：AMBIT BIOSCIENCES CORP

  公开号：WO2015031613A1

  公开（公告）日：2015-03-05

  Biaryl acetamide compounds and compositions and their methods of use are provided for modulating the activity of class III receptor tyrosine kinases and for the treatment, prevention or amelioration of one or more symptoms of disease of disorder mediated by class III receptor tyrosine kinases.

  双芳基乙酰胺化合物及其组合物以及它们的使用方法被提供用于调节III类受体酪氨酸激酶的活性，以及用于治疗、预防或改善由III类受体酪氨酸激酶介导的疾病或紊乱的一个或多个症状。
• Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
  申请人：Graziano P. Michael

  公开号：US20050096307A1

  公开（公告）日：2005-05-05

  The present invention provides compositions, therapeutic combinations and methods including: (a) at least one lipid modulating agent; and (b) at least one substituted azetidinone or substituted β-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols or 5α-stanols.

  本发明提供了包括以下内容的组合物、治疗组合和方法：(a)至少一种脂质调节剂；和(b)至少一种取代的噁唑烷酮或取代的β-内酰胺甾醇吸收抑制剂，可用于治疗血管疾病、糖尿病、肥胖以及降低血浆中甾醇或5α-甾烷醇的水平。